• General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

Article

Barrier takes second dermatologic product into Canada

Princeton, N.J.--Barrier Therapeutics Inc., a pharmaceutical company that specializes in dermatologic products, is now marketing and selling Vaniqa Cream (SkinMedica) in Canada.

Princeton, N.J.-Barrier Therapeutics Inc., a pharmaceutical company that specializes in dermatologic products, is now marketing and selling Vaniqa Cream (SkinMedica) in Canada.

Vaniqa (eflornithine hydrochloride) is a topical prescription product used for slowing the growth of excessive facial hair in women. It has been approved for such use by Health Canada. Princeton-based Barrier acquired the exclusive rights to distribute Vaniqa in Canada from Shire Pharmaceutical Contracts Ltd. in June.

Barrier also sells and markets another product, Solagé Topical Solution (Galderma) for age spots, in Canada.

Related Videos
Benjamin Lockshin, MD, FAAD, is featured in this series.
Benjamin Lockshin, MD, FAAD, is featured in this series.
Benjamin Lockshin, MD, FAAD, is featured in this series.
1 KOL is featured in this series.
2 KOLs are featured in this series.
1 KOL is featured in this series.
2 KOLs are featured in this series.
E. James Song is featured in this video series.
E. James Song is featured in this video series.
© 2024 MJH Life Sciences

All rights reserved.